MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity-Reference-Cited by-同舟云学术

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

Published:2012-09 Issue:9 Volume:7 Page:1337-1344
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Sakai Asao,Kasahara Kazuo,Ohmori Tohru,Kimura Hideharu,Sone Takashi,Fujimura Masaki,Nakao Shinji

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. EGFR and cancer prognosis;Nicholson;Eur J Cancer,2001

2. The EGF receptor family as targets for cancer therapy;Mendelsohn;Oncogene,2000

3. Epidermal growth factor receptors in non-small cell lung cancer;Veale;Br J Cancer,1987

4. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival;Veale;Br J Cancer,1993

5. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure–Activity Relationship of FL118 Platform Position 7 Versus Position 9-Derived Compounds and Their Mechanism of Action and Antitumor Activity;Journal of Medicinal Chemistry;2023-12-15

2. The Effect of the Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras) Proto-Oncogene, GTPase Genetic Polymorphism on the Safety and Efficacy of Bevacizumab Combination Treatment Regimens for Patients with Nonsquamous, Non-Small Cell Lung Cancer with Brain Metastases;Genetic Testing and Molecular Biomarkers;2022-05-01

3. FL118, acting as a ‘molecular glue degrader’, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy;Clinical and Translational Medicine;2022-05

4. Role of plant derived bioactive compounds against cancer;South African Journal of Botany;2021-11

5. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma;Journal of Experimental & Clinical Cancer Research;2021-08-12